Drug application
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE (LAMIVUDINE, NEVIRAPINE, ZIDOVUDINE)
Drugs@FDA NDA 203076 · CIPLA LTD
Key facts
| Drug name | LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE |
|---|---|
| Active ingredients | LAMIVUDINE, NEVIRAPINE, ZIDOVUDINE |
| Application type | NDA |
| Application number | 203076 |
| Company | CIPLA LTD |
| Dosage forms | TABLET, ORAL SUSPENSION |
| Strength | 30MG; 50MG; 60MG |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission class | Type 3 - New Dosage Form and Type 4 - New Combination |
| Latest submission status date | Oct 16, 2012 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: